Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer

BACKGROUND: Osimertinib is an essential drug to treat non-small-cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation, and rebiopsy is necessary to detect this mutation. However, the significance of repeat rebiopsy in NSCLC patients whose first rebiopsy was T7...

Descripción completa

Detalles Bibliográficos
Autores principales: Ichihara, Eiki, Hotta, Katsuyuki, Kubo, Toshio, Higashionna, Tsukasa, Ninomiya, Kiichiro, Ohashi, Kadoaki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047679/
https://www.ncbi.nlm.nih.gov/pubmed/30034635
http://dx.doi.org/10.18632/oncotarget.25705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047679/
https://www.ncbi.nlm.nih.gov/pubmed/30034635
http://dx.doi.org/10.18632/oncotarget.25705

Ejemplares similares